Ohr Pharmaceutical Inc. was granted additional time to regain compliance with Nasdaq's minimum $1 bid price listing requirement.

The pharmaceutical company now has an additional 180 calendar days, or until April 2, 2018, to meet the listing standard.

It had received the noncompliance notice April 6 and had until Oct. 3 to regain compliance.